Evidence map›Paper›PMID 41982275›Full record

ArticleACS materials letters2026

Biomimetic Protein Materials for Adjuvant-Free Dermal Penetration.

Marianna T P Favaro, Eric Voltà-Durán, Julieta M Sánchez, Elvira Escribano-Ferrer, Vanesa Huaca, Eva Miranda-Tovar, Ugutz Unzueta, Eloi Parladé, Esther Vázquez, Ramon Mangues and 2 more

Abstract read
In one paragraph

Article in ACS materials letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Marianna T P FavaroInstitut de Biotecnologia i de Biomedicina (IBB), Universitat Autònoma de Barcelona, 08320 Barcelona, Spain.ORCID https://orcid.org/0000-0003-2942-247X
Eric Voltà-DuránInstitut de Biotecnologia i de Biomedicina (IBB), Universitat Autònoma de Barcelona, 08320 Barcelona, Spain.
Julieta M SánchezInstitut de Biotecnologia i de Biomedicina (IBB), Universitat Autònoma de Barcelona, 08320 Barcelona, Spain.
Elvira Escribano-FerrerDepartment of Pharmacy, Pharmaceutical Technology and Physical Chemistry, School of Pharmacy and Food Sciences, University of Barcelona, 08028 Barcelona, Spain.ORCID https://orcid.org/0000-0001-7837-9506
Vanesa HuacaCentro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina, Instituto de Salud Carlos III, 08034 Barcelona, Spain.
Eva Miranda-TovarCentro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina, Instituto de Salud Carlos III, 08034 Barcelona, Spain.
Ugutz UnzuetaCentro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina, Instituto de Salud Carlos III, 08034 Barcelona, Spain.ORCID https://orcid.org/0000-0001-5119-2266
Eloi ParladéInstitut de Biotecnologia i de Biomedicina (IBB), Universitat Autònoma de Barcelona, 08320 Barcelona, Spain.ORCID https://orcid.org/0000-0001-5750-550X
Esther VázquezInstitut de Biotecnologia i de Biomedicina (IBB), Universitat Autònoma de Barcelona, 08320 Barcelona, Spain.
Ramon ManguesCentro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina, Instituto de Salud Carlos III, 08034 Barcelona, Spain.
Antonio VillaverdeInstitut de Biotecnologia i de Biomedicina (IBB), Universitat Autònoma de Barcelona, 08320 Barcelona, Spain.ORCID https://orcid.org/0000-0002-2615-4521
Isolda CasanovaCentro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina, Instituto de Salud Carlos III, 08034 Barcelona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The effective dermal delivery of functional proteins could substantially improve therapeutic options for common skin disorders, in which current lipid-based or invasive strategies face efficacy and safety limitations. We report a biomimetic protein depot platform based on granular, nontoxic amyloids generated through Zn-mediated coordination of hexahistidine-tagged proteins. Functionalization of these materials with either the cell-penetrating peptide R9 or the tight junction modulator c-CPE, the C-terminal region of the

Identifiers

PMID41982275
PMCPMC13073729

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.